Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A nice CEO blog/update would be welcome
https://glaucomafoundation.org/about-tgf/medical-advisory-board/
See link. Look who sits with Dr Murray (author of previous post)…. Our guy !!!! Jeffrey M. Liebmann, MD
Repurposing metformin for glaucoma proposed. October 5, 2023
Murray Fingeret, OD, FAAO
https://reviewofpresbyopia.com/repurposing-drugs-for-glaucoma/
The company also has its eye on locations in Hobbs or Gallup.
https://www.bizjournals.com/albuquerque/news/2023/10/09/lazydaze-opens-in-albuquerque.html
Primary Open-Angle Glaucoma + Metformin
*
Results: 240 participants acquired a diagnosis of POAG during all available follow-up time, while 18,200 did not. In bivariate analysis, metformin use was significantly associated with a lower odds of developing POAG (odds ratio [OR] 0.32, 95% confidence interval [CI] 0.23-0.42, p<0.001).
https://diabetesjournals.org/diabetes/article/72/Supplement_1/207-LB/150157/207-LB-Association-of-Metformin-Use-with-Primary#
Concern is however the lack of interest from non-retail buyers.
Would like to see a fund or two step in and take position… this would be a positive sign and retail would join in.
Key Words. Metformin + Glaucoma. This is where this thing is going per latest updates.
Metformin May Lower Odds of Primary Open-Angle Glaucoma in Patients with Diabetes
June 27, 2023
https://www.hcplive.com/view/metformin-protect-primary-open-angle-glaucoma-patients-diabetes
Dr. Jeffrey M. Liebmann graduated from Boston University School of Medicine, completed his ophthalmology residency at the State University of New York/Downstate Medical Center, and his glaucoma fellowship at the New York Eye and Ear Infirmary. Dr. Liebmann serves as Shirlee and Bernard Brown Professor, Vice-Chair, and Director of the Glaucoma Division of the Department Ophthalmology at Columbia University Irving Medical Center. Dr. Liebmann serves as a member of the World Glaucoma Association Council, Board of Directors of The Glaucoma Foundation and Secretary-Treasurer of the New York Glaucoma Society. Dr. Liebmann is a past-President of the World Glaucoma Association, American Glaucoma Society, and the New York Society for Clinical Ophthalmology, Emeritus Editor-in Chief of Journal of Glaucoma and was co-founder of the New York Glaucoma Research Institute, the American Glaucoma Society Foundation and ASCRS Glaucoma Day.
In addition to maintaining a busy tertiary-care referral practice in New York City, Dr. Liebmann is Principal Investigator for the NIH African Descent and Glaucoma Evaluation Study (ADAGES) and Ocular Hypertension Treatment Study (OHTS III) at Columbia University
Agreed
Definitely interesting info … looking for some real communication from CUBT
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421975/
In conclusion, our results demonstrate that IMT504 has an effect not only at the immunological level, as we described previously (Bianchi et al., 2016), but also directly on ß-cells in the diabetic condition. These results are in agreement with our previous results in STZ-induced diabetic rats, in which the immune system does not play a role in diabetes development, and a marked IMT504-induce recovery of ß-cells was observed (Bianchi et al., 2010). Thus, our data support the fact that part of the effects of IMT504 observed in vivo are due to direct effects on ß-cell function, increasing its potential as a therapy for diabetes.
That immunotech is NYSE pubco
https://aimimmuno.com/stock-information/
22Mil market cap…. Looking like they have interest in our IMT504 for a separate indication ??
3 companies listed under that 1 therapeutic together. And that MidAtlantic now inactive. See link. All 3 active in Florida together.
https://synapse.patsnap.com/drug/89f5a7bb9f62490c99d86172550a90a3
Active Organization:
Curative Biotechnology, Inc.
ARScience Biotherapeutics Inc.
Immunotech
https://aimimmuno.com/
Ocala Florida!!
Maybe another partner in the making.
Trying to piece this together on my own.
https://www.arsciencebio.com/
Boca Raton Florida!!!
Partnering with CUBT maybe????
Therapeutic Areas
Eye Diseases,
Infectious Diseases
Active Indication
Rabies,
Retinal Diseases
Inactive Indication
B-Cell Chronic Lymphocytic Leukemia,
Breast Cancer,
Diabetes Mellitus
+ [5]
Originator Organization
Immunotech
Active Organization
Curative Biotechnology, Inc.
ARScience Biotherapeutics Inc.
Immunotech
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421975/
Physiol Rep. 2023 Aug; 11(15): e15790. Published online 2023 Aug 11. doi: 10.14814/phy2.15790
New indication proposed: Thus, topical metformin can be a therapeutic strategy for managing ocular inflammation associated with diabetes.
Journal of Pharmaceutical Sciences
Volume 112, Issue 9, September 2023, Pages 2494-2505
Pharmaceutics, Drug Delivery and Pharmaceutical Technology
Ocular Delivery of Metformin for Sustained Release and in Vivo Efficacy
Where is CUBT LEADERSHIP!!!
Interesting 2024 setting up here
Omg!! Started the Finra corporate action again!! Going for name change and ticker symbol => $medh = daze
— the 1 & Only HANS (@The1OnlyHans) October 5, 2023
update. 3rd time the charm!#cantstopwontstop
Engaged with attorney this weekend to get us out of EM and get this name change complete!$medh SH came through.
— the 1 & Only HANS (@The1OnlyHans) October 1, 2023
OTC Current when?
Lots of good news wasted that could have invited investors
Paul Michaels gives a “like” on LinkedIn for Janssen and Takeda Pharmaceuticals. Both have ophthalmic interest. He is reading up/following on something it appears.
If you're a $medh investor.
— the 1 & Only HANS (@The1OnlyHans) September 9, 2023
Repost and share on #LinkedIn #LFG pic.twitter.com/2BI9fK2X2i
Here we go!
— the 1 & Only HANS (@The1OnlyHans) September 9, 2023
Doing 2M raise. conv note. Bridge loan
launching the franchise = 100 units sold in 3 years and potential IPO
DM for deck and more info.
Don't waste my time please.
I will respect yours.
New ticker symbol?
https://www.morningstar.com/stocks/pinx/daze/quote
Good morning back in Texas! Great soft opening weekend in New Mexico@DazedBrands & @Lazydazeco & $medh are officially in the legal cannabis market. Time to scale & fast!! License and franchise opportunities now available. 100 stores !! Ready , set , grow! #lfg #growth #OTC
— the 1 & Only HANS (@The1OnlyHans) September 5, 2023
MEDH Current. Next DAZE
Update for $MEDH shareholders.
— the 1 & Only HANS (@The1OnlyHans) August 24, 2023
We will get current again! #OTC @DazedBrands pic.twitter.com/MyrlmrBDzD
Hans post.
Alright!! Let's get this done! OMW back to #ABQ. #Roadtrip last one! Time to sell coffee & weed. Writing a little part of history.$medh with @lazydazeco & @DazedBrands. #CannabisCommunity #cannabislounge Not even the $MSOs have what we bout to launch. GET READY! pic.twitter.com/CqjKzzGuJR
— the 1 & Only HANS (@The1OnlyHans) August 21, 2023
Nah no one believes you pdgood
Gary is not Hans
Hans is not Gary
Mark is not Hans
Hans is not Mark
View profile for Hans Enriquez
Hans Enriquez
CEO / Chairman - Dazed Inc. ($medh) OTC
1d Edited
Check this out, we have these three fully operational coffee shops in the Austin area that are ready to go! These Turnkey shops come with built-out spaces and are owner-financed. Plus, the landlord has approved them for a hemp and CBD coffee shop.
If you're interested in partnering or investing, DM today! This opportunity won't last long. You can choose to franchise, partner, license, or rebrand.
One of the shops is located in Round Rock, Texas, while another is in Pflugerville, Texas. The third is located just blocks from UT Austin. Don't miss out on this exciting opportunity to join the booming coffee industry in the Austin area.
see below. snippets and criteria from our franchise presentation.
A Witness can still be CEO of a publicly traded company!
Come on pdgood, do better.
Not accurate statement you made.
This analysis does not address the association of metformin with incidence or progression of AMD.
From my understanding CUBT is not in the prevention business nor cure business… they are in the “Disease-Modifying” business.
They will imo study the Disease Modifying outcomes of ophthalmic drops on active AMD patients.